FOSUN HEALTH Logo

Pituitary Tumor Treatment

catalogue

Pituitary Tumor Treatment

Pituitary Tumor Treatment

There are four main options, and which applies depends on the hormone the tumour makes, its size, what it is pressing on, and the patient's own circumstances. A small tumour producing nothing needs nothing but a schedule. A tumour producing prolactin is usually treated with medication first, which commonly lowers the hormone and shrinks the tumour. Most other hormone-producing tumours, and any tumour pressing on the optic nerves, are usually treated with an operation through the nose. Radiation is reserved for a residual or recurring tumour, or for one that still overproduces a hormone after surgery.

How the decision is made

Four findings decide which option applies, and they are weighed together rather than one at a time:

  • Which hormone does it make? This is the single most decisive question, because the treatment of a functioning tumour is the treatment of its hormone. A prolactin-producing tumour is treated with medication first; a growth hormone- or ACTH-producing tumour is usually treated with surgery first; a tumour making nothing is treated for its size and its pressure, if it is treated at all.
  • Is sight at risk? Any compression of the optic chiasm moves the decision towards treatment without unnecessary delay, because the nerve fibres that have been displaced have a better chance of recovering than those damaged by prolonged pressure.
  • How large is it, and which way has it grown? Upwards towards the chiasm, sideways into the cavernous sinus, downwards into the sphenoid sinus. The direction determines whether the tumour can be reached from below, and what can be preserved.
  • Is the healthy gland still working? Any deficiency is identified and replaced before treatment, not afterwards — particularly cortisol, because an unreplaced deficiency becomes dangerous around an operation or during an illness.

Two principles follow. The first is that the ordering of the two problems matters. A tumour that both makes a hormone and presses on the chiasm has two issues that are dealt with in a deliberate order, and the order is decided once, by the specialties together. The second is that this is a condition managed over years: the hormone levels, the imaging and the visual fields continue to be followed after treatment, and the plan is revisited when any of them changes rather than being fixed at the outset.

Observation with scans at intervals

For a small tumour producing nothing, and pressing on nothing important, observation is a genuine option rather than a failure to decide:

  • Which tumours are observed — a non-functioning tumour that is small, not touching the optic chiasm, and not causing any hormone deficiency. This commonly includes tumours found incidentally, while imaging was done for an unrelated reason.
  • What the schedule looks like — an MRI at a defined interval, together with the hormone panel and the visual fields, because a tumour can change in size without changing the hormones and vice versa. The dates are given in writing and each scan is compared with the previous one.
  • What would end the observation — growth towards the optic chiasm, a new field defect, the appearance of a hormone in excess, or the development of a hormone deficiency that needs replacing.
  • Why it is reasonable rather than a delay — because many small non-functioning tumours change very little over years, and because an operation in this area carries risks to the healthy gland and, in some cases, to the sense of smell, which are not worth taking for a tumour that is doing nothing.
  • What still has to be done while observing — keeping the schedule, keeping the hormone tests alongside the scans, and reporting a change in vision straight away rather than waiting for the next appointment.

Medication, and when it comes first

For one type of pituitary tumour, medication is the treatment of first choice rather than an adjunct — and understanding which type is worthwhile:

  • Dopamine agonists for a prolactin-producing tumour. These medicines act on the same receptor the gland uses to control prolactin. They usually lower the prolactin level and shrink the tumour, often quite quickly, which is why they come first and why surgery may never be needed. They are taken for the long term, with the dose adjusted on the hormone results, and the prolactin is monitored rather than the medicine stopped once it normalises.
  • Somatostatin analogues for acromegaly. These reduce growth hormone production and are used where surgery has not controlled the hormone, and in some patients before surgery. A growth hormone receptor antagonist is used in selected patients whose hormone remains high; it blocks the effect of the hormone rather than its production, so it is monitored differently.
  • Medication to control cortisol in Cushing's disease. Used where surgery is not possible, has not controlled the disease, or is needed to bring cortisol down before an operation. Several agents act at different points in cortisol production, and the choice depends on availability, tolerance and the response of the cortisol level.
  • What medication does not do. It does not make the tumour disappear in every case, it usually needs to be continued rather than completed, and it does not remove the need for follow-up imaging and hormone testing. It also carries its own side effects, which is why the dose is the lowest that controls the hormone.

Surgery: through the nose, not through the skull

Most pituitary tumours that need an operation are removed through the nose, and the approach is worth understanding because it determines the recovery:

  • Endoscopic transsphenoidal surgery — an endoscope is passed through the nostrils and the sphenoid sinus, which sits directly beneath the pituitary hollow. There is no incision on the head, and the tumour is reached from below, which is the shortest route to it and the reason recovery is usually quicker than from a craniotomy.
  • What it aims to do — remove the tumour while leaving the healthy gland, the optic nerves and the structures of the cavernous sinus intact. For a functioning tumour the aim includes bringing the hormone down, and the hormone level after the operation is part of how success is judged.
  • How the direction of growth changes the operation — a tumour reaching into the cavernous sinus may be removed only in part, because the nerves to the eye muscles and the carotid artery run through it; a tumour that has grown upwards requires the chiasm to be decompressed deliberately.
  • What is expected afterwards — a short hospital stay, a period of nasal congestion and advice about blowing the nose and lifting, and a check of the hormone panel afterwards, since the gland's function can change once the tumour is removed. Diabetes insipidus, if it occurs, is usually temporary and is managed with desmopressin.
  • When a second operation is considered — where the hormone remains high and imaging suggests residual tumour that can be reached; where it cannot, radiation or medication is the next step rather than another operation by default.

Radiation, reserved for defined situations

Radiation is effective here, but it is used in a defined place in the sequence rather than as a first choice:

  • When it is used — for a residual tumour after surgery, for a tumour that recurs, and for a functioning tumour whose hormone remains high after surgery where medication is not controlling it or is not tolerated.
  • Stereotactic radiosurgery and fractionated radiotherapy — a single precisely aimed session for a small residual, or treatment in several sessions where the tumour is close to the optic chiasm, because the chiasm can tolerate divided doses better than a single high dose.
  • How its effect is measured — slowly. Control of tumour growth and control of hormone production both take time to appear, so the follow-up imaging and hormone testing continue for years, and medication is often continued in the meantime.
  • What it asks in return — the risk of new hormone deficiency over the years is the principal long-term concern, which is why the healthy pituitary function is tested at intervals after radiation; the visual apparatus is close by and is protected by the planning.

Hormone replacement, which belongs to every pathway

Whatever is done about the tumour, the gland itself may need supporting — and this part of the treatment is easy to overlook and important not to:

  • Cortisol — replaced where the adrenal axis is failing, with the dose increased during illness, fever or before an operation. This is the replacement that matters most, because an untreated deficiency can become an emergency.
  • Thyroid hormone — replaced where thyroid function is low, interpreted together with TSH because the pituitary may be the cause rather than the thyroid gland.
  • Sex hormones — replaced where the gonadal axis has failed, which matters for bone density and wellbeing as well as for fertility, and which is planned deliberately when fertility is a goal.
  • Growth hormone in selected adults — considered where the axis has failed, with the decision made on the hormone results and on symptoms rather than routinely.
  • Desmopressin — used where the back of the gland or the stalk is affected and water balance is disturbed, and which requires monitoring because both over- and under-replacement cause trouble.
  • Fertility counselling — arranged before treatment where a pregnancy is wanted, since both the tumour and its treatment affect the ability to conceive, and the timing of a pregnancy relative to treatment is a decision to make in advance rather than afterwards.

How the plan is made and reviewed

This condition sits between more specialties than most tumours of its size, and the plan is best made once rather than in sequence:

  • Endocrinology establishes which hormone the tumour makes, which functions are failing, and what replacement is needed — and follows the hormone levels for years afterwards.
  • Neurosurgery assesses what an operation could achieve and preserve, and how the direction of growth determines the approach.
  • Neuro-ophthalmology measures the visual fields before and after treatment, and is the specialty that decides when a change in vision requires the plan to move faster.
  • Radiation oncology assesses whether radiosurgery has a role, and plans the dose around the chiasm and the residual tumour.
  • Genetics contributes where an inherited syndrome is suspected, before the surveillance plan is fixed.
  • One written plan, with dates, listing which hormone tests, scans and field tests are due and when, what replacement is being taken and how the dose changes in illness, and who to contact between reviews.

Frequently Asked Questions

Will I need surgery, or can medication handle it?

For a prolactin-producing tumour, medication usually comes first and often handles it: dopamine agonists commonly bring the prolactin down and shrink the tumour, and surgery may never be needed. For most other hormone-producing tumours, and for any tumour pressing on the optic chiasm, an operation through the nose is usually the first step, with medication used afterwards to control a hormone that remains high. A small tumour producing nothing may need no treatment at all beyond a schedule. So the answer depends on the hormone, which is why that is the first thing to establish.

Is the operation through the skull?

Almost always not. Most pituitary tumours are removed endoscopically through the nostrils and the sphenoid sinus, which sits directly beneath the pituitary hollow — the shortest route to the tumour, with no incision on the head. Patients typically have a short hospital stay and a period of nasal congestion, with instructions about blowing the nose and lifting for a while afterwards. A craniotomy is reserved for unusual situations, such as a tumour that has grown in a direction the transsphenoidal route cannot reach, and it is worth asking explicitly which approach is planned and why.

Will the tumour come back?

It may, and what happens then is usually a defined next step rather than a return to the beginning. A residual tumour after surgery is common where it extended into the cavernous sinus or upwards, and it is followed with imaging and hormone testing; if it grows or continues to overproduce a hormone, radiation or a change of medication is considered. Because control of both growth and hormone production after radiation appears slowly, the follow-up continues for years, and that follow-up — with dates and intervals — is the part of the plan that makes recurrence manageable rather than surprising.

What about having children?

Fertility deserves to be raised early rather than at the end, for two reasons. A prolactin-producing tumour commonly causes the fertility problem itself, and treating it often restores ovulation or sperm production — so the discussion is part of the treatment rather than separate from it. And both the tumour and its treatment can affect the ability to conceive, which means the timing of a pregnancy relative to surgery, medication or radiation is a decision best made in advance. Ask to be referred for fertility counselling before treatment if a pregnancy is wanted, and ask specifically how the plan would change.

Send the scan and the hormone results, get the options set out

How the hormone and the vision together decide the next step is the question this file answers. Send the MRI images with their reports and dates, the hormone results with the reference ranges of the laboratory that performed them, and the visual field printouts. Add the operative or radiotherapy record, and the current medication with any replacement doses, if treatment has already begun. Endocrinology, neurosurgery and neuro-ophthalmology return a written assessment within 48 hours of the file being complete.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*